Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy
Abstract Breast cancer is highly sensitive to systemic therapy. High probability of pathological complete response suggests a clinical question that omitting surgery is an effective alternative to surgery in breast cancer showing clinical complete response to primary systemic therapy. However, the v...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of clinical oncology 2020-05, Vol.50 (6), p.629-634 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 634 |
|---|---|
| container_issue | 6 |
| container_start_page | 629 |
| container_title | Japanese journal of clinical oncology |
| container_volume | 50 |
| creator | Shigematsu, Hideo Fujisawa, Tomomi Shien, Tadahiko Iwata, Hiroji |
| description | Abstract
Breast cancer is highly sensitive to systemic therapy. High probability of pathological complete response suggests a clinical question that omitting surgery is an effective alternative to surgery in breast cancer showing clinical complete response to primary systemic therapy. However, the validity of omitting surgery for early breast cancer after primary systemic therapy has not been sufficiently established; thus, even if pathological complete response is expected in patients showing clinical complete response, excision of the primary tumor site remains the standard treatment of breast cancer. Inappropriate omitting surgery increases the incidence of local recurrence, which can be the risk of a subsequent distant metastasis and reduced overall survival. To achieve acceptable local control rate, omitting surgery should be investigated in patients with early breast cancer where a high percentage of pathological complete response, a high concordance rate between clinical complete response and pathological complete response and an acceptable local control rate are expected. This review presents concept and ongoing clinical trials for omitting surgery for patients with breast cancer showing clinical complete response to primary systemic therapy.
High rates of clinical complete response and pathological complete response suggest that omitting surgery is an effective alternative to surgery in breast cancer showing remarkable response to primary systemic therapy. |
| doi_str_mv | 10.1093/jjco/hyaa055 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2399839135</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jjco/hyaa055</oup_id><sourcerecordid>2399839135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-8b475143d834aabd1a0703709b4e699aa599444ad0171c1d3bbe4d6b6c14f14d3</originalsourceid><addsrcrecordid>eNp9kL1PwzAQRy0EoqWwMSNvMBBq13YSj6jiS6rUBebo4lzaVEkcbEco_z2pWhAT093w9PTTI-SaswfOtJjvdsbOtwMAU-qETLmMVSTiBT_980_Ihfc7xphKZXJOJmIhkjRheko266YKoWo31Pdug26gpXUUwdUDzR2CD9RAa9BRv7Vfe87UVVsZqKmxTVdjQOrQd7b1SIOlnasaGC1-8AGbytCwRQfdcEnOSqg9Xh3vjHw8P70vX6PV-uVt-biKjFQ8RGkuE8WlKFIhAfKCA0uYGJfmEmOtAZTWUkooGE-44YXIc5RFnMeGy5LLQszI3cHbOfvZow9ZU3mDdQ0t2t5nC6F1KjQXakTvD6hx1nuHZXYcn3GW7dNm-7TZMe2I3xzNfd5g8Qv_tByB2wNg--5_1TfJboWU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399839135</pqid></control><display><type>article</type><title>Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Shigematsu, Hideo ; Fujisawa, Tomomi ; Shien, Tadahiko ; Iwata, Hiroji</creator><creatorcontrib>Shigematsu, Hideo ; Fujisawa, Tomomi ; Shien, Tadahiko ; Iwata, Hiroji</creatorcontrib><description>Abstract
Breast cancer is highly sensitive to systemic therapy. High probability of pathological complete response suggests a clinical question that omitting surgery is an effective alternative to surgery in breast cancer showing clinical complete response to primary systemic therapy. However, the validity of omitting surgery for early breast cancer after primary systemic therapy has not been sufficiently established; thus, even if pathological complete response is expected in patients showing clinical complete response, excision of the primary tumor site remains the standard treatment of breast cancer. Inappropriate omitting surgery increases the incidence of local recurrence, which can be the risk of a subsequent distant metastasis and reduced overall survival. To achieve acceptable local control rate, omitting surgery should be investigated in patients with early breast cancer where a high percentage of pathological complete response, a high concordance rate between clinical complete response and pathological complete response and an acceptable local control rate are expected. This review presents concept and ongoing clinical trials for omitting surgery for patients with breast cancer showing clinical complete response to primary systemic therapy.
High rates of clinical complete response and pathological complete response suggest that omitting surgery is an effective alternative to surgery in breast cancer showing remarkable response to primary systemic therapy.</description><identifier>ISSN: 1465-3621</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyaa055</identifier><identifier>PMID: 32378709</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><ispartof>Japanese journal of clinical oncology, 2020-05, Vol.50 (6), p.629-634</ispartof><rights>The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020</rights><rights>The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-8b475143d834aabd1a0703709b4e699aa599444ad0171c1d3bbe4d6b6c14f14d3</citedby><cites>FETCH-LOGICAL-c451t-8b475143d834aabd1a0703709b4e699aa599444ad0171c1d3bbe4d6b6c14f14d3</cites><orcidid>0000-0003-3202-5512</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32378709$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shigematsu, Hideo</creatorcontrib><creatorcontrib>Fujisawa, Tomomi</creatorcontrib><creatorcontrib>Shien, Tadahiko</creatorcontrib><creatorcontrib>Iwata, Hiroji</creatorcontrib><title>Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>Abstract
Breast cancer is highly sensitive to systemic therapy. High probability of pathological complete response suggests a clinical question that omitting surgery is an effective alternative to surgery in breast cancer showing clinical complete response to primary systemic therapy. However, the validity of omitting surgery for early breast cancer after primary systemic therapy has not been sufficiently established; thus, even if pathological complete response is expected in patients showing clinical complete response, excision of the primary tumor site remains the standard treatment of breast cancer. Inappropriate omitting surgery increases the incidence of local recurrence, which can be the risk of a subsequent distant metastasis and reduced overall survival. To achieve acceptable local control rate, omitting surgery should be investigated in patients with early breast cancer where a high percentage of pathological complete response, a high concordance rate between clinical complete response and pathological complete response and an acceptable local control rate are expected. This review presents concept and ongoing clinical trials for omitting surgery for patients with breast cancer showing clinical complete response to primary systemic therapy.
High rates of clinical complete response and pathological complete response suggest that omitting surgery is an effective alternative to surgery in breast cancer showing remarkable response to primary systemic therapy.</description><issn>1465-3621</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kL1PwzAQRy0EoqWwMSNvMBBq13YSj6jiS6rUBebo4lzaVEkcbEco_z2pWhAT093w9PTTI-SaswfOtJjvdsbOtwMAU-qETLmMVSTiBT_980_Ihfc7xphKZXJOJmIhkjRheko266YKoWo31Pdug26gpXUUwdUDzR2CD9RAa9BRv7Vfe87UVVsZqKmxTVdjQOrQd7b1SIOlnasaGC1-8AGbytCwRQfdcEnOSqg9Xh3vjHw8P70vX6PV-uVt-biKjFQ8RGkuE8WlKFIhAfKCA0uYGJfmEmOtAZTWUkooGE-44YXIc5RFnMeGy5LLQszI3cHbOfvZow9ZU3mDdQ0t2t5nC6F1KjQXakTvD6hx1nuHZXYcn3GW7dNm-7TZMe2I3xzNfd5g8Qv_tByB2wNg--5_1TfJboWU</recordid><startdate>20200507</startdate><enddate>20200507</enddate><creator>Shigematsu, Hideo</creator><creator>Fujisawa, Tomomi</creator><creator>Shien, Tadahiko</creator><creator>Iwata, Hiroji</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3202-5512</orcidid></search><sort><creationdate>20200507</creationdate><title>Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy</title><author>Shigematsu, Hideo ; Fujisawa, Tomomi ; Shien, Tadahiko ; Iwata, Hiroji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-8b475143d834aabd1a0703709b4e699aa599444ad0171c1d3bbe4d6b6c14f14d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shigematsu, Hideo</creatorcontrib><creatorcontrib>Fujisawa, Tomomi</creatorcontrib><creatorcontrib>Shien, Tadahiko</creatorcontrib><creatorcontrib>Iwata, Hiroji</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shigematsu, Hideo</au><au>Fujisawa, Tomomi</au><au>Shien, Tadahiko</au><au>Iwata, Hiroji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2020-05-07</date><risdate>2020</risdate><volume>50</volume><issue>6</issue><spage>629</spage><epage>634</epage><pages>629-634</pages><issn>1465-3621</issn><eissn>1465-3621</eissn><abstract>Abstract
Breast cancer is highly sensitive to systemic therapy. High probability of pathological complete response suggests a clinical question that omitting surgery is an effective alternative to surgery in breast cancer showing clinical complete response to primary systemic therapy. However, the validity of omitting surgery for early breast cancer after primary systemic therapy has not been sufficiently established; thus, even if pathological complete response is expected in patients showing clinical complete response, excision of the primary tumor site remains the standard treatment of breast cancer. Inappropriate omitting surgery increases the incidence of local recurrence, which can be the risk of a subsequent distant metastasis and reduced overall survival. To achieve acceptable local control rate, omitting surgery should be investigated in patients with early breast cancer where a high percentage of pathological complete response, a high concordance rate between clinical complete response and pathological complete response and an acceptable local control rate are expected. This review presents concept and ongoing clinical trials for omitting surgery for patients with breast cancer showing clinical complete response to primary systemic therapy.
High rates of clinical complete response and pathological complete response suggest that omitting surgery is an effective alternative to surgery in breast cancer showing remarkable response to primary systemic therapy.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>32378709</pmid><doi>10.1093/jjco/hyaa055</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-3202-5512</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-3621 |
| ispartof | Japanese journal of clinical oncology, 2020-05, Vol.50 (6), p.629-634 |
| issn | 1465-3621 1465-3621 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2399839135 |
| source | Oxford University Press Journals All Titles (1996-Current); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T01%3A28%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Omitting%20surgery%20for%20early%20breast%20cancer%20showing%20clinical%20complete%20response%20to%20primary%20systemic%20therapy&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Shigematsu,%20Hideo&rft.date=2020-05-07&rft.volume=50&rft.issue=6&rft.spage=629&rft.epage=634&rft.pages=629-634&rft.issn=1465-3621&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyaa055&rft_dat=%3Cproquest_cross%3E2399839135%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2399839135&rft_id=info:pmid/32378709&rft_oup_id=10.1093/jjco/hyaa055&rfr_iscdi=true |